Biosimilar and interchangeable: Inseparable scientific concepts?
- PMID: 31486117
- PMCID: PMC6848899
- DOI: 10.1111/bcp.14089
Biosimilar and interchangeable: Inseparable scientific concepts?
Keywords: biological; biosimilar; biosimilarity; interchangeability; interchangeable; switch.
Conflict of interest statement
M.C‐S. has worked as a speaker for Roche, Sanofi, and Astra Zeneca in the previous 5 years and no other relationships or activities that could appear to have influenced the submitted work. M‐A.A. works, or has worked, as a speaker and/or consultant for Biogen, Novartis, Kern Pharma, Lilly, Amgen, Sanofi, Celgene, MSD, Pfizer, Amgen, and Roche in the previous 5 years and no other relationships or activities that could appear to have influenced the submitted work. J.G. has served as a speaker, a consultant, and advisory member for or has received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, Biogen, Takeda, Janssen, Roche, Sandoz, Celgene, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, and Vifor Pharma. F.M. works, or has worked, as a speaker and/or consultant for Amgen, Adium, Asofarma, Biogen, Finox, Gebro, Hikma, Hospira, KernPharma, Lilly, Merck Serono, Mylan, Oli Med, Sandoz, Stada, Theramex, and Roche, in the last 5 years, and there are no other relationships or activities that could appear to have influenced the submitted work. A.B. has received honoraria as an advisor and speaker and grants from Pfizer, Abbvie, Roche, UCB, Gilead, Sandoz, Novartis, Lilly, Nordic, Sanofi and Amgen. R.M. is currently working at Sandoz Iberia. M.W. is currently working at Sandoz Biopharmaceuticals c/o Hexal AG. R.D. has received honoraria as a consultant and/or speaker for Amgen, Astellas, Bristol Myers‐Squibb, Celgene, Genzyme, Gilead Sciences, Incyte, Jazz Pharmaceuticals, Kiadis Pharma, Merck Sharp and Dohme, Novartis, Omeros, Pfizer, Sanofi Oncology and Therakos‐Mallinckrodt in the previous five years, and no other relationships or activities that could appear to have influenced the submitted work. J‐M.C. has received consulting/speaker fees and/or has acted as a board member and/or has acted as PI/SI for Novartis, Janssen, Eli Lily, Celgene, Almirall, Leo Pharma, Abbvie, Sandoz, Mylan and Pfizer, and no other relationships or activities that could appear to have influenced the submitted work.The other authors have no competing interests to declare.
None of the authors has received funding in the form of honoraria, or any other compensation, for the writing of this paper. The views, thoughts, and opinions expressed in this Commentary belong solely to the authors. They do not intend to reflect necessarily the position of the authors' employer, organization, or learned society to which they belong.
References
-
- European Medicines Agency and the European Commission. Biosimilars in the EU Information guide for healthcare professionals. 2017. Available from: https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-g.... Accessed February 19, 2019.
-
- Lamanna WC, Holzmann J, Cohen HP, et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion Biol Ther. 2018;18(4):369‐379. - PubMed
-
- Reichel C. Differences in sialic acid O‐acetylation between human urinary and recombinant erythropoietins: a possible mass spectrometric marker for doping control. Drug Test Anal. 2013;5(11–12):877‐889. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources